Ask AI
ProCE Banner Activity

ACHILES: Randomized Phase II Study of Atezolizumab vs Observation After Chemoradiotherapy for Limited-Stage SCLC

Conference Coverage
Slideset

In the randomized phase II ACHILES trial, although well tolerated, treatment with atezolizumab vs observation in patients with LS SCLC with CR/PR/SD following CRT did not significantly improve progression-free or overall survival.

Released: June 06, 2025

Expiration: December 05, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar